Analyst Price Target is $9.00
▲ +374.93% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Palisade Bio in the last 3 months. The average price target is $9.00, with a high forecast of $25.00 and a low forecast of $2.00. The average price target represents a 374.93% upside from the last price of $1.90.
Current Consensus is
Buy
The current consensus among 10 polled investment analysts is to buy stock in Palisade Bio. This rating has held steady since May 2026, when it changed from a Moderate Buy consensus rating.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Read More
